<DOC>
	<DOCNO>NCT02766140</DOCNO>
	<brief_summary>The present trial perform evaluate whether SHR1020 combination docetaxel patient Local Advanced Metastatic recurrent Non Squamous NSCLC effective compare placebo combination docetaxel . A secondary aim obtain safety information well information quality life patient treat SHR1020 combination docetaxel .</brief_summary>
	<brief_title>SHR1020 Plus Docetaxel Compared Placebo Plus Docetaxel 2nd Line Non Squamous Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1. age:1870 year 2 . Histologically cytologically confirm locally advanced and/or metastatic NSCLC recurrent NSCLC ( ≤9 month date diagnosis randomize ) , epidermal growth factor receptorwild type , Anaplastic Lymphoma Kinasewild type unknown mutation 3 . At least one lesion accurately measure received local treatment radiotherapy cryotherapy 4 . Relapse failure one first line prior platinumbased chemotherapy 5 . Eastern Cooperative Oncology Group performance status 0 1 6 . Life expectancy least 12 week 7 . Adequate organ bone marrow function define ( blood transfusion drug leucopenia Platelet within 14 day screen ) : ( 1 ) HB≥90g/l ( 2 ) ANC≥1.5×10^9/l ( 3 ) PLT≥100×10^9/l ( 4 ) BIL＜1.25×upper limit normal ( 5 ) Alanine Aminotransferase and/or AST＜2.5×upper limit normal ( ＜ 5×upper limit normal patient liver metastasis ) ( 6 ) Cr≤1.25×upper limit normal Creatinine clearance rate＞45ml/min ( CockcroftGault Formula ) ( 7 ) Cholesterol≤1.5×upper limit normal , Triglyceride≤2.5×upper limit normal ( 8 ) Left ventricular ejection fraction ( LVEF ) great low limit normal 8 . Female : child bear potential , negative urine serum pregnancy test result within 7 day randomisation , agree use effective contraception treatment least 6 month end treatment ; male : agree use effective contraception treatment least 6 month end treatment 9 . Patient give write informed consent 1 . More one prior chemotherapy regimen advance and/or metastatic recurrent NSCLC ( except neoadjuvant adjuvant chemotherapy ) 2 . Previous therapy VEGFR inhibitors、recombinant human endostatin、 docetaxel immunotherapy treatment NSCLC 3 . History severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 ( Tween 80 ) , Hypersensitivity excipients trial drug contrast medium 4 . Have clinically significant cavity effusion , pleural effusion、 pericardial effusion ascites require clinical intervention 5 . Active brain metastasis 6 . Other malignancy within past ( include primary brain tumor Leptomeningeal tumor ) , basal cell skin cancer carcinoma situ cervix 7 . Significant weight loss ( ＞10 % ) within past 6 week 8 . Persistence clinically relevant therapy relate toxicity previous therapy ( great Common Terminology Criteria Adverse Event ( CTCAE ) 4.0 grade 1 ) 9 . Treatment surgery , chemotherapy , hormone therapy , radiotherapy , immunomodulation monoclonal antibody therapy within past 4 week traditional chinese medicine antitumor therapy within past 2 week start therapy 10 . Radiographical evidence cavitary necrotic tumour 11 . Centrally locate tumours radiographical evidence ( CT MRI ) local invasion major blood vessel 12 . Greater CTCAE 4.0 grade 2 pulmonary hemorrhage within past one month screen 13 . History clinically significant haemoptysis within past 3 month ( half teaspoon within 24 hour ) 14 . History major thrombotic clinically relevant major bleed event past 6 month 15 . Prothrombin time ( PT ) and/or partial thromboplastin time ( PTT ) &gt; 50 % devi ation upper limit normal 16 . Application anticoagulant vitamin K antagonist warfarin , heparin analogus , INR≤1.5 , purpose prevention , use lowdose warfarin ( 1mg , qd ) aspirin ( ≤ 100 mg per day ) allow 17 . Incomplete wound heal fracture long time 18 . Uncontrolled hypertensin one antihypertensive agent , unstable angina , history myocardial infarction past 6 month , congestive heart failure＞NYHA II , serious cardiac arrhythmia 19 . Urinary protein≥++ confirm 24hour urinary protein great 1.0g ; 20 . Preexisting thyroid dysfunction , even medical therapy , thyroid function maintain normal range 21 . Uncontrolled diabetes mellitus antidiabetic therapy 22 . Current peripheral neuropathy great CTCAE 4.0 grade 2 23 . Active chronic hepatitis C and/or B infection liver dysfunction 24 . History immunodeficiency disease , acquire congenital immunodeficiency disease , history organ transplantation 25 . Serious infection require systemic antibiotic therapy 26 . Variety factor affect oral medication ( unable swallow , chronic diarrhea , bowel obstruction gastrointestinal disorder abnormality 27 . Pregnancy breast feed 28 . Active alcohol drug abuse 29 . Treatment another clinical trial within past 4 week start therapy 30 . Psychological , familial , sociological , geographical factor potentially hamper compliance study protocol followup schedule 31 . According investigator , condition may increase risk associate patient safety study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>